Genome breakthrough heralds cancer innovations Jeff Nesmith - Cox Washington Bureau Sunday, May 28, 2006 Washington --- An explosion of scientific discovery...
[Originally seen on nhl-info] Study: Tumors inhibit immune system SEATTLE, May 29 (UPI) -- Seattle scientists have shown that tumors can manipulate the immune...
ASCO Updates Guidelines for Use of Antiemetics in Cancer Therapy By Martha Kerr NEW YORK (Reuters Health) May 30 - The American Society of Clinical Oncology...
BlankChemical in Plastics Is Tied to Prostate Cancer By Marla Cone The Los Angeles Times Thursday 01 June 2006 Bisphenol A, found in baby bottles and microwave...
BlankJune 2, 2006 Drug for Bones Is Newly Linked to Jaw Disease By GINA KOLATA In the last 10 years, millions of patients have taken a class of drugs that can...
[From Karl's nhl-info list. The website noted below has a nice explanation of gene therapy. So far, the field has been fraught with problems. However, work ...
Case Western Reserve University Cancer worries continue long after treatment ends Case researchers find in long-term cancer survivors CLEVELAND -- The doctor...
BlankJune 4, 2006 New Drug Holds Promise for Type of Breast Cancer By ANDREW POLLACK ATLANTA, June 3 — For women with a certain type of breast cancer, the...
BlankLLOYD OLD: TWO STEPS AHEAD As a medical student at the University of California, San Francisco, Dr. Old became fascinated with the idea that the immune...
BlankJune 5, 2006 New Drugs for Cancer Could Soon Flood Market By ANDREW POLLACK ATLANTA, June 4 — Big Pharma has discovered cancer. For several years...
Published online: 4 June 2006; | doi:10.1038/news060529-12 Mice testicles reveal new class of RNAs Mini cousins of DNA could play vital role in sperm...
Efficacy of SMIP-016, a novel CD37-directed biologic therapy, in human NHL tumor xenograft models. Meeting: 2006 ASCO Annual Meeting Abstract No: 2565 ...
Hematologic malignancies developing in previously healthy individuals who received hematopoietic growth factors: Implications for use of colony stimulating...
Immune evasion by melanoma and ovarian tumor cells through upregulation of the immunosuppressive molecule CD200. Meeting: 2006 ASCO Annual Meeting Abstract...
Risk of malignancy associated with chronic lymphocytic leukemia: A population based Canadian study. Meeting: 2006 ASCO Annual Meeting Abstract No: 20020 ...
Preliminary results from two phase II studies of lenalidomide monotherapy in relapsed/refractory non-Hodgkin's Lymphoma. Meeting: 2006 ASCO Annual Meeting ...
Flavopiridol, fludarabine and rituximab (FFR) is an active regimen in indolent B-cell lymphoproliferative disorders and mantle cell lymphoma (MCL). Meeting:...
Hypogammaglobulinemia increases the risk of chemotherapy associated febrile neutropenia in patients with chronic lymphocytic leukemia. Meeting: 2006 ASCO...
Immune anemias in patients with chronic lymphocytic leukemia treated with chemoimmunotherapy regimen of fludarabine, cyclophosphamide and rituximab as initial...
A phase I trial of PS-341 and fludarabine for relapsed and refractory indolent non-Hodgkin's lymphoma and chronic lymphocytic leukemia. Meeting: 2006 ASCO...
The effect of changes in the treatment paradigm for chronic lymphocytic leukemia: A tumor registry study. Meeting: 2006 ASCO Annual Meeting Abstract No: 16000...
Pooled safety analysis of oblimersen alone or with fludarabine and cyclophosphamide in patients with advanced chronic lymphocytic leukemia. Meeting: 2006 ASCO...
Having problems with message search?
Fill out this form to ensure your group is one of the first to be migrated to the new message search system.
